Boehringer Ingelheim’s weight-loss drug candidate survodutide could also be effective for liver disease metabolic dysfunction-associated steatohepatitis (MASH), if the results of a mid-stage ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

We're All Ears for Celebrity Buzz! Please enter a name. Please enter a valid email. Please enter a phone number. Please enter a message. Send the Tip! Us Weekly has affiliate partnerships so we ...